Pricing Log in Create free account

ACADIA Pharmaceuticals Inc. (ACAD) vs Relay Therapeutics, Inc. (RLAY)

ACADIA Pharmaceuticals Inc. and Relay Therapeutics, Inc. are both Biotechnology companies. ACADIA Pharmaceuticals Inc. and Relay Therapeutics, Inc. are of similar size ($3.7B and $3.7B). Relay Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ACADIA Pharmaceuticals Inc. trades at 10.0×. ACADIA Pharmaceuticals Inc. grew revenue faster over the last twelve months: 14.8% against −74.3%. ACADIA Pharmaceuticals Inc. has the higher net margin (30.1% vs −2,594.2%) and the higher return on invested capital (18.6% vs 0.00%). Across the 17 metrics below, ACADIA Pharmaceuticals Inc. leads on 15 and Relay Therapeutics, Inc. on 2.

Valuation

Metric ACAD RLAY Biotechnology median
P/E 10.00 n/m 10.26
P/S 3.06 313.49 9.18
P/B 2.65 3.88 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 28.06 n/m 0.65
EV/Sales 2.24 230.87 8.98
Earnings yield 10.00% (9.21%) (34.89%)
Free cash flow yield (3.15%) (6.15%) (24.52%)

Profitability

Metric ACAD RLAY Biotechnology median
Gross margin 90.48% 100.00% 65.16%
Operating margin 10.17% (2,815.49%) 0.00%
Net margin 30.13% (2,594.20%) 0.00%
Free cash flow margin 6.82% (1,924.59%) 0.00%
Return on equity 31.43% (36.77%) (50.12%)
Return on assets 23.18% (33.72%) (45.60%)
Return on invested capital 18.60% 0.00% 0.00%

Growth

Metric ACAD RLAY Biotechnology median
Revenue growth (TTM) 14.82% (74.29%) 6.26%
EPS growth (last fiscal year) 69.12% 31.78% 29.88%
Revenue growth, 5-year CAGR 19.39% (28.58%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACAD RLAY Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.82 18.27 4.89
Net debt to EBITDA (7.37) 1.84 1.01

Dividend

Metric ACAD RLAY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACAD RLAY Biotechnology median
Market cap 3.66b 3.73b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack